Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H
2335.HK
Hong Kong Stock Exchange37.50
HKD
+1.54
- -
ISIN
CNE100007Q79
Return %
Stock
S&P500
1Y
1.63
19.99
3Y
1.63
68.07
5Y
1.63
72.03
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Bing Wang
- Full Time Employees
- 121
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building 6 Xi'an SA People's Republic of China
- IPO Date
- Jun 24, 2026
- Website
- micot.cn
- Similar Companies
- Business
- Shaanxi Micot Pharmaceutical Technology Co., Ltd. is a biotechnology company engaged in the discovery, development and commercialization of bi-/multi-specific peptide drugs for the treatment of metabolic diseases, cardiovascular and cerebrovascular disorders, cancer, and neurological conditions. The company operates a vertically integrated platform spanning research and development, preclinical and clinical development, manufacturing process development (CMC) and regulatory affairs to support end-to-end translation from laboratory research to commercial products. Its core product pipeline includes a Core Product currently advancing through late-stage clinical trials, complemented by multiple product candidates across different stages of development. Headquartered in Xi’an, Shaanxi Province, China, Micot maintains operational bases across key Chinese innovation hubs, including its R&D and operations headquarters in Xi’an, a clinical and regulatory center in Beijing and a large-molecule development platform in Shanghai, enabling an integrated ecosystem for peptide drug discovery, optimization, manufacturing scale-up and regulatory submission. The company is listed on The Stock Exchange of Hong Kong (ticker: 2335.HK), reflecting its status as a public biotechnology enterprise with a strategic emphasis on peptide therapeutics as a cornerstone modality. Main products and services: discovery and validation of bi-/multi-specific peptide drug candidates; preclinical research and translational science; Phase I–III clinical development support; process development and manufacturing for biologics and large-molecule peptides; regulatory strategy and filings; quality assurance, pharmacovigilance and post-market surveillance; contract research and development services; strategic collaboration and co-development partnerships; commercialization and market access support; intellectual property development and management. Latest major company changes: the company pursues ongoing strategic partnerships and licensing agreements to expand its clinical portfolio and geographic reach; recent corporate disclosures reflect exceptions related to governance and capital markets activities, including participation in funding rounds and potential acquisitions or reorganizations to strengthen its research capabilities and manufacturing scale; the firm periodically announces product candidate updates, new collaboration agreements and expansions of its research facilities to support accelerated development timelines. Industry context and targets: operates within biotechnology and medical research with emphasis on peptide therapeutics for metabolic, cardiovascular, cerebrovascular, oncologic and neurological indications; targets biopharma and contract development partners, academic collaborations and health systems seeking innovative peptide-based therapies; geographic focus centers on China with expanding collaborations and potential international partnerships to support global commercialization. Subsidiaries and parent relationships are organized to enable cross-regional development and regulatory alignment, with a unified corporate governance framework under the listed entity in Hong Kong.